CPT2 and pancreatic adenocarcinoma: In liver hepatocellular Carcinoma (LIHC), lung adenocarcinoma (LUAD), kidney renal clear cell carcinoma (KIRC), thyroid carcinoma (THCA), pancreatic adenocarcinoma (PAAD), and stomach adenocarcinoma (STAD), low levels of CPT2 expression were found to be related with a poor overall survival (OS), according to an investigation of the Kaplan-Meier Plottr database.